The bill amends Minnesota Statutes 2024, section 152.126, to enhance the prescription monitoring program by changing the terminology from "controlled substances" to "reportable substances." This change includes a definition of "reportable" substances, which now encompasses specific drugs like butalbital and FDA-approved opioid antagonists for overdose reversal. The amendments clarify the responsibilities of dispensers and prescribers, indicating that dispensers are not required to report certain prescriptions under specific circumstances, such as for patients in healthcare facilities or those receiving drug samples. Additionally, prescribers are mandated to check the prescription monitoring data before issuing prescriptions for certain reportable substances, with exceptions for situations like palliative care or emergencies.

The bill also introduces new provisions regarding the access and management of data related to opioid treatment programs, requiring the board to maintain a log of all individuals accessing this data for at least three years. It allows the board to participate in an interstate prescription monitoring program, ensuring that data access is restricted according to established guidelines. Furthermore, the commissioner of human services is tasked with establishing a system for routine access to data for monitoring clients in opioid treatment programs. The bill emphasizes compliance and audit responsibilities for permissible users, limits access to data on opioid antagonists, and grants patients the right to request information about who has accessed their data, along with a formal process for such requests.

Statutes affected:
Introduction: 152.126